Patients with hidradenitis suppurativa (HS) who had higher resilience levels experienced a smaller decrease in health-related quality of life (HRQOL) as depressive symptoms increased, according to a recent study. This cross-sectional survey study of 154 patients from 2 referral centers in the US and in Denmark was conducted from June 1, 2016, to March 31, 2017. Patients were considered eligible if they were aged ≥18 years and had a visit for HS at 1 of the 2 referral centers in the past 2 years. The main outcome of interest was the HRQOL as measured by the Dermatology Life Quality Index. Researchers found:
- The rate of depression among the patients in this study was comparable to those reported in previous studies; 55 patients (35.7%) were classified as having depression, and 32 patients (20.8%) had borderline depressive symptoms.
- Patient-rated HS severity and the depression score each independently estimated 27% and 10% of variation in HRQOL, respectively.
- The interaction term for resilience and depression was significant, indicating that resilience moderates depression.
Kirby JS, Butt M, Esmann S, Jemec GBE. Association of resilience with depression and health-related quality of life for patients with hidradenitis suppurativa. [Published online ahead of print November 8, 2017]. JAMA Dermatol. doi:10.1001/jamadermatol.2017.3596.
Must Reads in Rare Diseases
Risk Prediction of In-Hospital Mortality for SJS/TEN, JAMA Dermatol; ePub 2019 Mar 6; Noe, et al
Lymph Node Ratio and Survival Post-MCC Surgery, JAMA Dermatol; ePub 2019 Mar 2; Cheraghlou, et al
Necrobiosis Lipoidica Linked with Diabetes, Obesity, JAMA Dermatology; ePub 2019 Feb 20; Hashemi, et al
List of medications linked to drug-induced lupus expands, Arnaud L et al. Ann Rheum Dis. 2019 Feb 4. doi: 10.1136/annrheumdis-2018-214598